Swiss National Bank Has $4.24 Million Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Swiss National Bank grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 94.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 79,100 shares of the company’s stock after purchasing an additional 38,400 shares during the quarter. Swiss National Bank’s holdings in Janux Therapeutics were worth $4,235,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of JANX. Rhumbline Advisers grew its stake in Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock valued at $2,043,000 after purchasing an additional 599 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock valued at $596,000 after buying an additional 1,095 shares during the last quarter. Virtu Financial LLC boosted its holdings in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after buying an additional 2,419 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Janux Therapeutics in the fourth quarter valued at $139,000. Finally, Zacks Investment Management increased its holdings in Janux Therapeutics by 8.7% during the third quarter. Zacks Investment Management now owns 42,133 shares of the company’s stock worth $1,914,000 after buying an additional 3,360 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 2.9 %

Janux Therapeutics stock opened at $30.83 on Wednesday. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -26.35 and a beta of 3.23. Janux Therapeutics, Inc. has a 12 month low of $28.92 and a 12 month high of $71.71. The stock’s 50 day moving average is $36.33 and its 200-day moving average is $46.31.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. purchased 110,206 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was bought at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the transaction, the director now owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $4,507,788.32. This represents a 13.97 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,002 shares of company stock worth $1,279,953. Corporate insiders own 29.40% of the company’s stock.

Analysts Set New Price Targets

JANX has been the subject of a number of recent analyst reports. Scotiabank cut their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. BTIG Research raised their target price on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Stifel Nicolaus upped their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Finally, Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Janux Therapeutics presently has a consensus rating of “Buy” and an average price target of $92.44.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.